📰 Belgian Transparency News
Belgian Transparency News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Belgian Transparency. Real-time updates on events, politics, business and more.
May 28, 2024
Regulatory News: In accordance with Article 14 of the Belgian Transparency law of May 2, 2007, Azelis Group NV (the Company) (Brussels:AZE) announces that it has received the following transparency
May 27, 2024
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM - May 27, 2024 - 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in
April 25, 2024
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – April 25, 2024 – 07:00 PM CET , a biopharmaceutical company headquartered in Leuven, today...
April 25, 2024
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – April 25, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on April 25, 2024, from Atlas Special Opportunities, LLC indicating that as of April 19, 2024, it held 380,75...
March 28, 2024
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
January 17, 2024
Regulated Information Leuven, BELGIUM – January 17, 2024 – 7:00 PM CET Oxurion NV , a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency...
January 12, 2024
Regulated Information Leuven, BELGIUM – January 12, 2024 – 8:00 AM CET Oxurion NV , a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency...
October 30, 2023
Regulated Information Leuven, BELGIUM, Boston, MA, US – October 30, 2023 – 8.00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a first transparency notification on October 27, 2023, from Atlas Spe...
October 20, 2023
Regulated Information Leuven, BELGIUM, Boston, MA, US – October 20, 2023 – 8.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company...
September 27, 2023
Regulated Information Leuven, BELGIUM, Boston, MA, US – September 27, 2023 – 7.00 PM CET Oxurion NV , a biopharmaceutical company developing next generation standard of care ophthalmic therapies,...